Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Quality of life under therapy with Aromasin® (exemestane) according to IBCSG (International
Breast Cancer Study Group) questionnaire.
Change of the endometrium after switching from tamoxifen to Aromasin® (exemestane).
Deeper knowledge of Adverse Events during routine administration.